Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates
Janet I Malowany, Paul Monagle, David C Knoppert, David SC Lee, John Wu, Patricia McCusker, M Patricia Massicotte, Suzan Williams, Anthony KC Chan
Thrombosis Research | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2008
INTRODUCTION: Enoxaparin is the current anticoagulant of choice for neonatal thrombosis. Present neonatal treatment guidelines of 1.5 mg/kg every 12 hours (q12 h) are extrapolated primarily from an earlier study with 9 infants less than 2 months of age. More recent studies indicate an increased dose requirement for neonates. MATERIALS AND METHODS: Relevant data from articles and abstracts were identified by searching MEDLINE and pediatric and hematology conference proceedings. RESULTS: Publications between 1996 and 2007 included 8 papers, 4 abstracts and 1 review article with primary research documenting enoxaparin use in 240 neonates. The mean maintenance dose of enoxaparin ranged from 1.48..View full abstract
Anthony Chan is a Career Investigator funded by the Heart and Stroke Foundation of Canada.